All In Biotech

Drug Trial Radar · NCT06916078

A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

A Phase 1, Multicenter, Sequential-Design, Single-Dose, Open-Label Study of Lepodisiran in Participants With Normal Hepatic Function and Participants With Mild, Moderate, or Severe Hepatic Impairment

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Apr 23, 2025

Primary completion

Jul 13, 2026

Study completion Jul 13, 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Apr 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants. The study will last up to approximately 9 weeks, excluding screening.

Conditions

  • Liver Dysfunction
  • Healthy

Interventions

  • LepodisiranDrug

    Lepodisiran administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LepodisiranTime frame: Baseline Up to 9 weeks
  2. PK: Maximum Concentration (Cmax) of LepodisiranTime frame: Baseline Up to 9 weeks

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Pharmacology of Miami

    Miami, Florida

  • Orlando Clinical Research Center

    Orlando, Florida

  • American Research Corporation at Texas Liver Institute

    San Antonio, Texas

  • CRU Early Phase Unit

    Kistarcsa, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.